LifeCycle Pharma Announces Positive Interim Results of Phase 2 Clinical Trial of LCP-Tacro for the Prevention of Organ Rejection in De Novo Kidney Transplant Patients.

LifeCycle Pharma A/S, announced positive interim results from a Phase 2 clinical trial involving 63 patients comparing LCP-Tacro tablets administered once daily versus Prograf capsules, administered twice daily in de novo kidney transplant patients. These data confirm the previous experience with LCP-Tacro in stable kidney and liver transplant patients announced in March and July 2008, respectively. These findings are further supported by interim preliminary 6-month follow-up data as the randomized transplant patients have progressed into the 1-year maintenance stage of the study. LCP will draw on these emerging data to form the basis for LCPs planning and preparation of the pivotal …